Potassium%252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCL) is an essential electrolyte used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia. * Prevention of hypokalemia, particularly in patients receiving diuretics or other medications that deplete potassium. ## Adult Dosing * **Oral:** * **Treatment of Hypokalemia:** Typical doses range from 20-100 mEq per day, divided into 2-4 doses. Mild hypokalemia may be treated with 40-60 mEq daily. Moderate to severe hypokalemia may require higher doses up to 100 mEq daily. Doses greater than 40 mEq per day should generally be administered in divided doses. Maximum single oral dose is typically 25 mEq. * **Prevention of Hypokalemia:** Typical doses range from 20-40 mEq per day, divided into 1-2 doses. * **Intravenous (IV):** * Dosing is highly individualized based on serum potassium levels, clinical status, and rate of correction desired. * **Treatment of Hypokalemia:** * In patients with *no ECG changes* and *serum potassium > 2.5 mEq/L*: Doses typically range from 10-20 mEq administered over 1-2 hours, up to a maximum of 40 mEq per 24 hours. * In patients with *ECG changes* or *serum potassium < 2.5 mEq/L*: Doses can be higher, but **must be administered via central venous access** at a rate no faster than 10 mEq/hour, up to a maximum of 40 mEq per 24 hours. Rates up to 20 mEq/hour may be used in life-threatening situations under continuous ECG monitoring with careful attention to urinary output. * **Maintenance:** Doses depend on ongoing losses and intake. * **Maximum concentration for peripheral IV administration:** Generally limited to 40 mEq/L to reduce phlebitis risk. * **Maximum concentration for central IV administration:** Can be higher (e.g., 100 mEq/L or more), but local protocols must be consulted. ## Pediatric Dosing * Dosing is weight-based and dependent on serum potassium levels and clinical condition. Exact dosing depends on local protocol and should be guided by serum potassium levels. * **Oral:** Typically 1-5 mEq/kg/day divided into 1-4 doses, not to exceed the adult maximum of 100 mEq/day. * **Intravenous (IV):** * **Treatment of Hypokalemia:** Typical doses range from 0.3-1 mEq/kg per dose, not to exceed 20 mEq per dose, infused over 1-3 hours. Total daily dose should generally not exceed 40 mEq/kg or 200 mEq, whichever is less. * **Rate of infusion:** Generally no faster than 0.3-0.5 mEq/kg/hour (or 1 mEq/kg/hour in specific, closely monitored situations). Maximum infusion rate is usually 1 mEq/kg/hour (or 40 mEq/hour, whichever is less). * **Concentration:** Maximum concentration for peripheral IV administration is typically 40 mEq/L. Higher concentrations may be used centrally. ## Dose Adjustments * **Renal Impairment:** Use with extreme caution or avoid. Potassium is renally excreted; impaired renal function can lead to hyperkalemia. Dose reduction or discontinuation is necessary. ## Contraindications * Hyperkalemia. * Conditions that may predispose to hyperkalemia, such as advanced renal failure, untreated Addison's disease, or anuria. * Certain instances of severe burns or crush injuries. * Intestinal obstruction or delayed gastric emptying (for oral extended-release formulations). ## Adverse Effects * **Common:** Nausea, vomiting, diarrhea, abdominal pain (oral). Phlebitis, pain at injection site (IV). * **Serious:** Hyperkalemia (most significant risk), cardiac arrhythmias, cardiac arrest, muscle weakness, paralysis, respiratory depression. ## Key Drug Interactions * **ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), Potassium-sparing diuretics (e.g., spironolactone, amiloride), Aldosterone antagonists (e.g., eplerenone), NSAIDs, Trimethoprim, Heparin:** Increased risk of hyperkalemia. Monitor potassium levels closely. * **Potassium supplements/salt substitutes:** Additive potassium load, increasing hyperkalemia risk. * **Diuretics (loop and thiazide):** Can cause potassium depletion, necessitating potassium replacement. However, concurrent use requires careful monitoring. * **Insulin:** Insulin promotes cellular uptake of potassium; administration can temporarily lower serum potassium. ## Monitoring * **Serum Potassium:** Crucial, especially during IV therapy or dose adjustments. Frequency depends on severity of hypokalemia, route of administration, and patient stability. * **Renal Function (BUN, Creatinine):** To assess risk of potassium accumulation. * **ECG:** For signs of hyperkalemia (peaked T waves, prolonged PR interval, loss of P waves, widening QRS complex) or hypokalemia (flattened T waves, U waves). * **Urinary Output:** Essential for safe IV potassium administration. * **Signs and Symptoms of Hypokalemia and Hyperkalemia:** Muscle weakness, fatigue, arrhythmias, paresthesias. ## Clinical Pearls * Oral potassium chloride can be irritating to the GI tract; administer with food or fluids to minimize gastrointestinal upset. * Never administer IV potassium undiluted or as a bolus injection due to the risk of cardiac arrest. * Always confirm the correct concentration and rate of infusion for IV potassium, particularly for pediatric patients. * Patients with severe hypokalemia (serum K < 2.5 mEq/L) and ECG changes require aggressive, closely monitored IV therapy, usually via a central line. * Potassium replacement should be guided by serum potassium levels and clinical assessment, not just the amount of potassium lost. *** **Disclaimer:** This information is intended for clinical pharmacy professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information, institutional protocols, and patient-specific factors before making clinical decisions.